Lantheus Holdings, Inc. (LNTH)

Market Cap	3.58B
Revenue (ttm)	1.52B
Net Income (ttm)	271.00M
Shares Out	67.99M
EPS (ttm)	3.77
PE Ratio	13.93
Forward PE	10.55
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,313,483
Open	50.50
Previous Close	51.84
Day's Range	49.67 - 52.72
52-Week Range	47.25 - 118.21
Beta	0.09
Analysts	Strong Buy
Price Target	85.50 (+62.33%)
Earnings Date	Nov 5, 2025

About LNTH

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked o...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Jun 25, 2015
• Employees: 808
• Stock Exchange: NASDAQ
• Ticker Symbol: LNTH
• Website: https://www.lantheus.com

Financial Performance

In 2024, Lantheus Holdings's revenue was $1.53 billion, an increase of 18.32% compared to the previous year's $1.30 billion. Earnings were $312.44 million, a decrease of -4.35%.

Analyst Summary

According to 6 analysts, the average rating for LNTH stock is "Strong Buy." The 12-month stock price target is $85.5, which is an increase of 62.33% from the latest price.

Price Target

$85.5

(62.33% upside)

Analyst Consensus: Strong Buy